Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases

IF 1.9 Q4 ONCOLOGY Cancer reports Pub Date : 2025-01-23 DOI:10.1002/cnr2.70122
Yayu Huang, Genwen Chen, Xian Zhang, Yang Qian, Jian Wang
{"title":"Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases","authors":"Yayu Huang,&nbsp;Genwen Chen,&nbsp;Xian Zhang,&nbsp;Yang Qian,&nbsp;Jian Wang","doi":"10.1002/cnr2.70122","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The optimal management strategy for Stage IV rectal cancer with potentially treatable liver metastases remains controversial, particularly regarding the role of pelvic radiotherapy (RT).</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>We intend to investigate the impact of pelvic RT on oncological outcomes of rectal cancer with potentially treatable liver metastasis.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>This retrospective study included 83 patients diagnosed with rectal cancer and synchronous liver metastases from June 2012 to January 2022. All patients underwent radical surgery for rectal cancer and treatment of synchronous liver metastases, as determined by a multidisciplinary team (MDT). We divided the 83 patients into two treatment groups: chemoradiotherapy and surgery (CRT + S) and chemotherapy and surgery (C + S). The CRT + S group (<i>n</i> = 40) received pelvic RT, systemic therapy, and liver metastasis treatment. The C + S group (<i>n</i> = 43) received systemic therapy and liver metastasis treatment only. A total of 83 patients were analyzed with a median follow-up of 45 months (range 12–127 months). In the CRT + S group, 48.2% (40/83) of patients underwent chemoradiotherapy, while the C + S group comprised 51.8% (43/83) of patients who received chemotherapy only. The CRT + S group demonstrated significantly longer local recurrence-free survival compared to the C + S group (median 37.5 vs. 34 months; <i>p</i> = 0.011). In addition, patients in the CRT + S group had a longer median overall survival (OS) compared to the C + S group (46.50 vs. 44.0 months; <i>p</i> = 0.0497). Notably, achieving no evidence of disease (NED) status after definitive treatment for both primary and liver metastases was associated with improved OS (<i>p</i> = 0.008).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study suggests that the addition of pelvic RT to multimodality therapy for patients with rectal cancer and potentially treatable liver metastases may improve local control and long-term survival. The findings support the consideration of RT in the clinical management of this patient population.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The optimal management strategy for Stage IV rectal cancer with potentially treatable liver metastases remains controversial, particularly regarding the role of pelvic radiotherapy (RT).

Aims

We intend to investigate the impact of pelvic RT on oncological outcomes of rectal cancer with potentially treatable liver metastasis.

Methods and Results

This retrospective study included 83 patients diagnosed with rectal cancer and synchronous liver metastases from June 2012 to January 2022. All patients underwent radical surgery for rectal cancer and treatment of synchronous liver metastases, as determined by a multidisciplinary team (MDT). We divided the 83 patients into two treatment groups: chemoradiotherapy and surgery (CRT + S) and chemotherapy and surgery (C + S). The CRT + S group (n = 40) received pelvic RT, systemic therapy, and liver metastasis treatment. The C + S group (n = 43) received systemic therapy and liver metastasis treatment only. A total of 83 patients were analyzed with a median follow-up of 45 months (range 12–127 months). In the CRT + S group, 48.2% (40/83) of patients underwent chemoradiotherapy, while the C + S group comprised 51.8% (43/83) of patients who received chemotherapy only. The CRT + S group demonstrated significantly longer local recurrence-free survival compared to the C + S group (median 37.5 vs. 34 months; p = 0.011). In addition, patients in the CRT + S group had a longer median overall survival (OS) compared to the C + S group (46.50 vs. 44.0 months; p = 0.0497). Notably, achieving no evidence of disease (NED) status after definitive treatment for both primary and liver metastases was associated with improved OS (p = 0.008).

Conclusion

This study suggests that the addition of pelvic RT to multimodality therapy for patients with rectal cancer and potentially treatable liver metastases may improve local control and long-term survival. The findings support the consideration of RT in the clinical management of this patient population.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
盆腔放疗治疗伴有同步可治疗肝转移的直肠癌患者。
背景:IV期直肠癌伴肝转移的最佳治疗策略仍存在争议,尤其是盆腔放疗(RT)的作用。目的:我们打算研究盆腔放疗对直肠癌伴肝转移的肿瘤预后的影响。方法与结果:本回顾性研究纳入2012年6月至2022年1月83例诊断为直肠癌并同步肝转移的患者。由多学科团队(MDT)确定的所有患者都接受了直肠癌根治性手术和同步肝转移治疗。我们将83例患者分为放化疗+手术(CRT + S)和化疗+手术(C + S)两组。CRT + S组(n = 40)接受盆腔放疗、全身治疗和肝转移治疗。C + S组(n = 43)仅接受全身治疗和肝转移治疗。共分析83例患者,中位随访时间为45个月(12-127个月)。在CRT + S组中,48.2%(40/83)的患者接受了放化疗,而C + S组仅接受化疗的患者占51.8%(43/83)。与C + S组相比,CRT + S组显示出更长的局部无复发生存期(中位37.5个月对34个月;p = 0.011)。此外,与C + S组相比,CRT + S组患者的中位总生存期(OS)更长(46.50个月vs 44.0个月;p = 0.0497)。值得注意的是,在原发性和肝转移的最终治疗后,无疾病证据(NED)状态与OS的改善相关(p = 0.008)。结论:本研究表明,对于直肠癌和潜在可治疗的肝转移患者,在多模式治疗中加入盆腔放疗可能改善局部控制和长期生存。研究结果支持在该患者群体的临床管理中考虑RT。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer reports
Cancer reports Medicine-Oncology
CiteScore
2.70
自引率
5.90%
发文量
160
审稿时长
17 weeks
期刊最新文献
Postoperative Adjuvant Chemoradiotherapy ± PD-1 Inhibitor for Locally Advanced Head and Neck Squamous Cell Carcinoma. Healing the Mind to Ease Pain and Fatigue: The Role of Attachment, Mindfulness, and Cognitive Emotion Regulation in Early-Stage Breast Cancer Survivors. Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report. Clinical Characteristics and Management of Two Cases of Complete Androgen Insensitivity Syndrome With Germ Cell Tumors The Bioinformatics and Experimental Analysis of CD276 for Prognosis and Immune Infiltrates in Colon Adenocarcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1